论文部分内容阅读
对54例未经治疗且无转移的晚期局限于头颈部鳞状细胞癌患者,给予顺铂(100mg/m_2,1天)、争光霉素(15mg静注,1天)及5-FU(650mg/m~2·d连续静注),争光霉素(16mg/m~2·d),21天重复1次。这项Ⅱ期研究的目的在于用化疗增加完全缓解率,确定影响局部控制及预后因素。1986年4月至1988年8月,本组54例中Ⅲ期5例,Ⅳ期49例(1986年UICC-AJCC标准)。患者均按上述方案治疗。30例(61％)的Ⅳ期疾病患者为大体积结节病变(9例N_2c和21例N_3),29例(53％)为T_4原发性损害。
For 54 untreated and metastatic patients with advanced squamous cell carcinoma limited to the head and neck, cisplatin (100 mg/m 2 for 1 day), bleomycin (15 mg intravenously, 1 day), and 5-FU (diffusion) were given. 650 mg/m~2 d continuous intravenous injection), bleomycin (16 mg/m~2 d), repeated once every 21 days. The purpose of this phase II study was to increase the rate of complete remission with chemotherapy and determine the factors that influence local control and prognostic factors. From April 1986 to August 1988, 54 cases of this group included 5 cases of stage III and 49 cases of stage IV (the UICC-AJCC standard of 1986). The patients were treated according to the above protocol. Thirty patients (61%) with stage IV disease were massive nodules (9 N2c and 21 N3) and 29 (53%) had T4 primary lesions.